Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATR
REST API REST API
Homo sapiens
ATR is differentially expressed in 298 experiments: 120 organism parts: kidney, liver, ... (118 more);, 206 disease states: normal, control, ... (204 more);, 87 cell types 346 cell lines 36 compound treatments and 69 other conditions.
Synonyms FRP1, MEC1, SCKL1, SCKL
Orthologs MEC1 (Saccharomyces cerevisiae)   ATR (Gallus gallus)   Atr (Rattus norvegicus)   ATR (Bos taurus)   Atr (Mus musculus)   ENSCING00000004150 (Ciona intestinalis)   atr (Danio rerio)   mei-41 (Drosophila melanogaster)   atr (Xenopus laevis)   ATR (Canis familiaris)   (Compare orthologs)
InterPro Term HEAT_type_2, UME, PIK_FAT, PIK-rel_kinase_FAT, FATC, PI3/4_kinase_cat
Gene Ontology Term DNA damage checkpoint, DNA binding, protein binding, phosphotransferase activity, alcohol group as acceptor, DNA repair, peptidyl-serine phosphorylation, negative regulation of DNA replication, ATP binding, cell cycle, multicellular organismal development, nucleus, nucleotide binding, protein serine/threonine kinase activity, nucleoplasm, cell cycle checkpoint, response to DNA damage stimulus, DNA replication, protein kinase activity, cellular response to gamma radiation, MutLalpha complex binding, regulation of protein binding, XY body, MutSalpha complex binding, PML body, cellular response to UV, positive regulation of DNA damage response, signal transduction by p53 class mediator, protein autophosphorylation, protein phosphorylation, replicative senescence
UniProt Accession Q13535, D6RIG7, D6RFJ6
Gene-Disease Assocation SECKEL SYNDROME 1; SCKL1
Search EB-eye ENSG00000175054
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
MOLT4
2
E-MTAB-62, E-MTAB-37
T84
2
E-MTAB-37, E-GEOD-1474
MDA-MB-231
1
2
E-TABM-420, E-GEOD-5823, E-MTAB-62
BC1
1
E-MTAB-37
ITM-E6E7-ST
1
E-GEOD-2487
340 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, ... (46 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CD19+ B cells (neg. sel.)
2
1
E-AFMX-5
dermal fibroblast
1
E-MEXP-1216
naive B cell
1
E-TABM-702
keratinocyte
1
E-GEOD-3204
81 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (65 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
3
E-MTAB-62, E-GEOD-96, E-MTAB-37, E-MEXP-2034
dermatomyositis
2
E-GEOD-1551, E-GEOD-5370
multiple myeloma
2
E-MTAB-62, E-GEOD-2113
cervical carcinoma
1
2
E-GEOD-5823, E-MTAB-62, E-MEXP-1331
colon carcinoma
1
2
E-MTAB-62, E-GEOD-3726, E-MTAB-37
nodal peripheral T-cell lymphoma
1
E-TABM-702
200 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-1417, E-TABM-782, E-GEOD-5824, ... (24 experiments)

Factor Value U/D Experiments
none
4
7
E-GEOD-5824, E-GEOD-20719, E-TABM-782, E-TABM-868, E-GEOD-7400, ... (11 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
actinomycin D
1
E-GEOD-6400
Cxcl12
1
1
E-GEOD-7307
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-MEXP-2280, E-TABM-147, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-GEOD-2466, E-GEOD-1926, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-GEOD-980, ... (8 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.233 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM